LTPA2017017I1 - Tetraciklinis junginys - Google Patents
Tetraciklinis junginysInfo
- Publication number
- LTPA2017017I1 LTPA2017017I1 LTPA2017017C LTPA2017017C LTPA2017017I1 LT PA2017017 I1 LTPA2017017 I1 LT PA2017017I1 LT PA2017017 C LTPA2017017 C LT PA2017017C LT PA2017017 C LTPA2017017 C LT PA2017017C LT PA2017017 I1 LTPA2017017 I1 LT PA2017017I1
- Authority
- LT
- Lithuania
- Prior art keywords
- tetracyclic compound
- tetracyclic
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009139691 | 2009-06-10 | ||
PCT/JP2010/059785 WO2010143664A1 (ja) | 2009-06-10 | 2010-06-09 | 4環性化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
LTPA2017017I1 true LTPA2017017I1 (lt) | 2017-06-26 |
LTC2441753I2 LTC2441753I2 (lt) | 2019-02-25 |
Family
ID=43308919
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP15180863.1T LT2975024T (lt) | 2009-06-10 | 2010-06-09 | Tetraciklininiai junginiai |
LT18158255T LT3345903T (lt) | 2009-06-10 | 2010-06-09 | Tetracikliniai junginiai |
LTPA2017017C LTC2441753I2 (lt) | 2009-06-10 | 2017-06-02 | Tetraciklinis junginys |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP15180863.1T LT2975024T (lt) | 2009-06-10 | 2010-06-09 | Tetraciklininiai junginiai |
LT18158255T LT3345903T (lt) | 2009-06-10 | 2010-06-09 | Tetracikliniai junginiai |
Country Status (39)
Country | Link |
---|---|
US (6) | US9126931B2 (lt) |
EP (4) | EP3613729A1 (lt) |
JP (2) | JP4588121B1 (lt) |
KR (1) | KR101351120B1 (lt) |
CN (1) | CN102459172B (lt) |
AR (1) | AR077025A1 (lt) |
AU (1) | AU2010259588B2 (lt) |
CA (1) | CA2764653C (lt) |
CL (1) | CL2011002433A1 (lt) |
CO (1) | CO6430460A2 (lt) |
CR (1) | CR20110492A (lt) |
CY (2) | CY1117752T1 (lt) |
DK (3) | DK3345903T3 (lt) |
EC (1) | ECSP12011573A (lt) |
ES (3) | ES2759510T3 (lt) |
FR (1) | FR17C1019I2 (lt) |
HK (1) | HK1165794A1 (lt) |
HR (3) | HRP20160605T1 (lt) |
HU (4) | HUE039167T2 (lt) |
IL (1) | IL216817A (lt) |
LT (3) | LT2975024T (lt) |
LU (1) | LUC00022I2 (lt) |
MA (1) | MA33418B1 (lt) |
MX (1) | MX2011013306A (lt) |
MY (1) | MY159850A (lt) |
NL (1) | NL300876I2 (lt) |
NO (2) | NO2975024T3 (lt) |
NZ (1) | NZ597477A (lt) |
PE (1) | PE20121065A1 (lt) |
PL (3) | PL2441753T3 (lt) |
PT (3) | PT2441753E (lt) |
RS (1) | RS58855B1 (lt) |
RU (2) | RU2585622C3 (lt) |
SG (1) | SG175707A1 (lt) |
SI (3) | SI2975024T1 (lt) |
TW (2) | TWI531367B (lt) |
UA (1) | UA107796C2 (lt) |
WO (1) | WO2010143664A1 (lt) |
ZA (1) | ZA201106938B (lt) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010143664A1 (ja) * | 2009-06-10 | 2010-12-16 | 中外製薬株式会社 | 4環性化合物 |
WO2012023597A1 (ja) | 2010-08-20 | 2012-02-23 | 中外製薬株式会社 | 4環性化合物を含む組成物 |
JP5006987B2 (ja) * | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | 4環性化合物を含む医薬 |
EP3815685A3 (en) * | 2011-10-31 | 2021-10-13 | The Methodist Hospital Research Institute | Compound comprising a mao targeting/seeker moiety for treating human gliomas |
WO2013134353A1 (en) | 2012-03-06 | 2013-09-12 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
AU2013321235B2 (en) | 2012-09-25 | 2017-07-20 | Chugai Seiyaku Kabushiki Kaisha | RET inhibitor |
JP2016503798A (ja) | 2012-12-20 | 2016-02-08 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化alk阻害剤 |
CN104968667B (zh) * | 2013-02-05 | 2017-06-20 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
CA2907663A1 (en) | 2013-04-02 | 2014-10-09 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
CN104109168B (zh) * | 2013-04-20 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
CN104130241A (zh) * | 2013-05-05 | 2014-11-05 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
CN104177332A (zh) * | 2013-05-20 | 2014-12-03 | 中国科学院上海药物研究所 | 酰胺基取代的吲哚并萘酮衍生物及其医药用途 |
CN104177342B (zh) * | 2013-05-21 | 2018-01-05 | 中国科学院上海药物研究所 | 杂环基取代的吲哚并萘酮衍生物及其医药用途 |
WO2014190949A1 (zh) * | 2013-06-01 | 2014-12-04 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
CN104230960B (zh) * | 2013-06-06 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
KR20160020502A (ko) | 2013-06-18 | 2016-02-23 | 노파르티스 아게 | 제약 조합물 |
CN104804016B (zh) * | 2014-01-23 | 2017-06-20 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
CA2946268A1 (en) | 2014-04-25 | 2015-10-29 | Chugai Seiyaku Kabushiki Kaisha | Crystal of tetracyclic compound |
EP3135287A4 (en) | 2014-04-25 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CA2942186C (en) * | 2014-06-18 | 2023-06-27 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising non-ionic surfactants |
TWI803187B (zh) * | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含4環性化合物的非晶質體之固體分散體及製劑 |
KR101909404B1 (ko) | 2014-09-29 | 2018-10-17 | 수안주 파마 코포레이션 리미티드 | 역형성 림프종 키나제의 폴리사이클릭 저해제 |
CN105566307B (zh) * | 2014-10-11 | 2019-04-23 | 中国科学院上海药物研究所 | 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途 |
CN104402862B (zh) * | 2014-11-12 | 2016-10-05 | 苏州明锐医药科技有限公司 | 艾立替尼的制备方法 |
KR102584344B1 (ko) | 2015-01-16 | 2023-09-27 | 추가이 세이야쿠 가부시키가이샤 | 병용 의약 |
US9573932B2 (en) * | 2015-03-02 | 2017-02-21 | Yong Xu | Synthesis of intermediates in the preparation of ALK inhibitor |
WO2016145288A1 (en) * | 2015-03-11 | 2016-09-15 | International Flavors & Fragrances Inc. | Processes for the preparation of unsaturated malonates |
AU2016251253B2 (en) | 2015-04-24 | 2020-07-09 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
US10508082B2 (en) | 2015-09-23 | 2019-12-17 | Dana-Farber Cancer Institute, Inc. | Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK |
CN105777710B (zh) * | 2016-04-05 | 2018-09-04 | 湖南欧亚药业有限公司 | 一种艾乐替尼的合成方法 |
CN106946650B (zh) * | 2017-03-01 | 2021-06-08 | 南京远淑医药科技有限公司 | 一种盐酸阿雷替尼中间体的合成方法 |
CN106928185B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
CN107129488A (zh) * | 2017-04-21 | 2017-09-05 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼的制备方法 |
CN106995433A (zh) * | 2017-04-21 | 2017-08-01 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼的制备方法 |
CN106928184B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
CN106892860B (zh) * | 2017-04-21 | 2019-08-02 | 湖南博奥德药业有限公司 | 一种艾乐替尼中间体的制备方法 |
CN106928125A (zh) * | 2017-04-21 | 2017-07-07 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼中间体的制备方法 |
CN107033125B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
CN107033124B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
BR112019022137A2 (pt) | 2017-05-04 | 2020-05-12 | Basf Se | Usos de compostos, compostos da fórmula i, composição agroquímica e método para combater fungos nocivos fitopatogênicos |
EP3649116A1 (en) * | 2017-07-05 | 2020-05-13 | Fresenius Kabi Oncology Limited | A process for preparing alectinib or a pharmaceutically acceptable salt thereof |
JP7054134B2 (ja) * | 2017-12-07 | 2022-04-13 | 国立大学法人京都大学 | ベンゾ[b]カルバゾール化合物及びそれを用いたイメージング |
AU2018382122B2 (en) * | 2017-12-13 | 2021-11-18 | Shanghaitech University | ALK protein degradation agent and anti-tumor application thereof |
CN108178743A (zh) * | 2018-02-08 | 2018-06-19 | 安庆奇创药业有限公司 | 一种艾乐替尼关键中间体的制备方法 |
US20220117982A1 (en) * | 2018-04-09 | 2022-04-21 | Shanghaitech University | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates |
WO2019211868A1 (en) * | 2018-04-30 | 2019-11-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile hydrochloride |
CN112384223A (zh) | 2018-06-29 | 2021-02-19 | 中外制药株式会社 | 含有难溶性碱性药剂的药物组合物 |
CA3107270A1 (en) * | 2018-09-04 | 2020-03-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing tetracyclic compound |
EP3856192A4 (en) * | 2018-09-27 | 2023-01-04 | Dana Farber Cancer Institute, Inc. | ALK-TARGETING DEGRADING AGENTS AND THEIR THERAPEUTIC USES |
CN109438218B (zh) * | 2018-10-23 | 2021-04-09 | 成都艾必克医药科技有限公司 | 一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法 |
CN109384664B (zh) * | 2018-11-20 | 2021-04-13 | 成都正善达生物医药科技有限公司 | 一种艾乐替尼中间体的制备方法 |
EP3556754A1 (en) | 2018-12-07 | 2019-10-23 | Fresenius Kabi iPSUM S.r.l. | Process for the preparation of alectinib |
CN111349012B (zh) * | 2018-12-21 | 2023-01-10 | 上海复星星泰医药科技有限公司 | 一种卤代芳烃类化合物的制备方法及其中间体 |
CA3124330A1 (en) | 2018-12-21 | 2020-06-25 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
CN110590739A (zh) * | 2019-09-20 | 2019-12-20 | 中国药科大学 | 一种艾乐替尼的制备方法 |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN116806152A (zh) | 2021-01-29 | 2023-09-26 | 中外制药株式会社 | 儿童癌症治疗用药物组合物 |
EP4320153A1 (en) | 2021-04-09 | 2024-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
CN115340523B (zh) * | 2021-05-12 | 2023-12-15 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种具有alk抑制活性的化合物及其制备方法和用途 |
WO2023161233A1 (en) * | 2022-02-22 | 2023-08-31 | Synthon B.V. | Solid forms of alectinib and alectinib salts |
CN115677659B (zh) * | 2022-10-11 | 2024-03-22 | 枣庄市润安制药新材料有限公司 | 一种阿雷替尼的制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0892090A (ja) * | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
DE69505470T2 (de) | 1994-08-04 | 1999-05-12 | Hoffmann La Roche | Pyrrolocarbazol |
JPH08291285A (ja) * | 1995-04-21 | 1996-11-05 | Fuji Photo Film Co Ltd | 感光性組成物及びそれを用いた要素 |
PL329681A1 (en) * | 1996-05-01 | 1999-04-12 | Lilly Co Eli | Halogen-substituted inhibitor of proteinous kinase c |
EP1178988B1 (en) * | 1999-05-14 | 2007-02-28 | The Australian National University | Compounds and therapeutic methods |
US7217709B2 (en) * | 2003-02-28 | 2007-05-15 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
ES2263862T3 (es) * | 2003-03-07 | 2006-12-16 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones. |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
US7378414B2 (en) * | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
WO2005054237A1 (en) | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
CA2548600A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
CN1934082A (zh) | 2004-03-19 | 2007-03-21 | 斯皮德尔实验股份公司 | 有机化合物 |
EP1730128A1 (en) | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
EA013678B1 (ru) * | 2004-08-26 | 2010-06-30 | Пфайзер Инк. | Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы |
GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
KR20080056288A (ko) * | 2005-11-07 | 2008-06-20 | 아이알엠 엘엘씨 | Ppar 조절제로서의 화합물 및 조성물 |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
US8063225B2 (en) * | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
CL2007003049A1 (es) * | 2006-10-23 | 2008-05-16 | Cephalon Inc Pharmacopeia Drug | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. |
CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
CN101754956B (zh) | 2007-07-20 | 2014-04-23 | 内尔维阿诺医学科学有限公司 | 作为具有激酶抑制剂活性的取代的吲唑衍生物 |
CA2707308C (en) | 2007-11-30 | 2016-08-02 | Newlink Genetics Corporation | Ido inhibitors |
EA201190235A1 (ru) | 2009-05-07 | 2012-05-30 | Астразенека Аб | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
WO2010143664A1 (ja) * | 2009-06-10 | 2010-12-16 | 中外製薬株式会社 | 4環性化合物 |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
WO2012023597A1 (ja) * | 2010-08-20 | 2012-02-23 | 中外製薬株式会社 | 4環性化合物を含む組成物 |
AU2013321235B2 (en) * | 2012-09-25 | 2017-07-20 | Chugai Seiyaku Kabushiki Kaisha | RET inhibitor |
EP3135287A4 (en) * | 2014-04-25 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CA2946268A1 (en) * | 2014-04-25 | 2015-10-29 | Chugai Seiyaku Kabushiki Kaisha | Crystal of tetracyclic compound |
CA2942186C (en) * | 2014-06-18 | 2023-06-27 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising non-ionic surfactants |
TWI803187B (zh) * | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含4環性化合物的非晶質體之固體分散體及製劑 |
-
2010
- 2010-06-09 WO PCT/JP2010/059785 patent/WO2010143664A1/ja active Application Filing
- 2010-06-09 PT PT107861957T patent/PT2441753E/pt unknown
- 2010-06-09 HU HUE15180863A patent/HUE039167T2/hu unknown
- 2010-06-09 PL PL10786195.7T patent/PL2441753T3/pl unknown
- 2010-06-09 ES ES18158255T patent/ES2759510T3/es active Active
- 2010-06-09 PT PT151808631T patent/PT2975024T/pt unknown
- 2010-06-09 JP JP2010526082A patent/JP4588121B1/ja active Active
- 2010-06-09 RU RU2011154150A patent/RU2585622C3/ru active Protection Beyond IP Right Term
- 2010-06-09 MX MX2011013306A patent/MX2011013306A/es active IP Right Grant
- 2010-06-09 DK DK18158255T patent/DK3345903T3/da active
- 2010-06-09 LT LTEP15180863.1T patent/LT2975024T/lt unknown
- 2010-06-09 HU HUE18158255A patent/HUE046402T2/hu unknown
- 2010-06-09 HU HUE10786195A patent/HUE028278T2/en unknown
- 2010-06-09 AR ARP100102015A patent/AR077025A1/es active IP Right Grant
- 2010-06-09 AU AU2010259588A patent/AU2010259588B2/en active Active
- 2010-06-09 MY MYPI2011004483A patent/MY159850A/en unknown
- 2010-06-09 KR KR1020117031143A patent/KR101351120B1/ko active Protection Beyond IP Right Term
- 2010-06-09 PL PL18158255T patent/PL3345903T3/pl unknown
- 2010-06-09 ES ES10786195.7T patent/ES2575084T3/es active Active
- 2010-06-09 NO NO15180863A patent/NO2975024T3/no unknown
- 2010-06-09 LT LT18158255T patent/LT3345903T/lt unknown
- 2010-06-09 PT PT181582552T patent/PT3345903T/pt unknown
- 2010-06-09 CN CN201080025574.4A patent/CN102459172B/zh active Active
- 2010-06-09 EP EP19201621.0A patent/EP3613729A1/en active Pending
- 2010-06-09 TW TW099118688A patent/TWI531367B/zh active
- 2010-06-09 PL PL15180863T patent/PL2975024T3/pl unknown
- 2010-06-09 SG SG2011072295A patent/SG175707A1/en unknown
- 2010-06-09 EP EP15180863.1A patent/EP2975024B1/en active Active
- 2010-06-09 DK DK10786195.7T patent/DK2441753T3/en active
- 2010-06-09 SI SI201031676T patent/SI2975024T1/en unknown
- 2010-06-09 PE PE2011002060A patent/PE20121065A1/es active IP Right Grant
- 2010-06-09 NZ NZ597477A patent/NZ597477A/en unknown
- 2010-06-09 DK DK15180863.1T patent/DK2975024T3/en active
- 2010-06-09 SI SI201031199A patent/SI2441753T1/sl unknown
- 2010-06-09 TW TW105101212A patent/TWI624457B/zh active
- 2010-06-09 EP EP10786195.7A patent/EP2441753B1/en active Active
- 2010-06-09 US US13/377,300 patent/US9126931B2/en active Active
- 2010-06-09 RS RS20110548A patent/RS58855B1/sr unknown
- 2010-06-09 RU RU2015156881A patent/RU2725140C2/ru active
- 2010-06-09 CA CA2764653A patent/CA2764653C/en active Active
- 2010-06-09 EP EP18158255.2A patent/EP3345903B1/en active Active
- 2010-06-09 MA MA34519A patent/MA33418B1/fr unknown
- 2010-06-09 SI SI201031961T patent/SI3345903T1/sl unknown
- 2010-06-09 ES ES15180863T patent/ES2668775T3/es active Active
- 2010-09-06 UA UAA201200237A patent/UA107796C2/ru unknown
- 2010-09-07 JP JP2010199935A patent/JP5628603B2/ja active Active
-
2011
- 2011-09-19 CR CR20110492A patent/CR20110492A/es unknown
- 2011-09-22 ZA ZA2011/06938A patent/ZA201106938B/en unknown
- 2011-09-30 CL CL2011002433A patent/CL2011002433A1/es unknown
- 2011-12-07 IL IL216817A patent/IL216817A/en active IP Right Grant
-
2012
- 2012-01-04 EC EC2012011573A patent/ECSP12011573A/es unknown
- 2012-01-06 CO CO12002119A patent/CO6430460A2/es active IP Right Grant
- 2012-06-29 HK HK12106400.7A patent/HK1165794A1/xx unknown
-
2015
- 2015-02-11 US US14/619,242 patent/US9440922B2/en active Active
-
2016
- 2016-06-02 CY CY20161100490T patent/CY1117752T1/el unknown
- 2016-06-06 HR HRP20160605TT patent/HRP20160605T1/hr unknown
- 2016-07-28 US US15/221,926 patent/US20160340308A1/en not_active Abandoned
-
2017
- 2017-06-01 FR FR17C1019C patent/FR17C1019I2/fr active Active
- 2017-06-02 NL NL300876C patent/NL300876I2/nl unknown
- 2017-06-02 LT LTPA2017017C patent/LTC2441753I2/lt unknown
- 2017-06-06 HU HUS1700026C patent/HUS1700026I1/hu unknown
- 2017-06-12 NO NO2017026C patent/NO2017026I2/no unknown
- 2017-06-14 LU LU00022C patent/LUC00022I2/fr unknown
- 2017-07-12 CY CY2017026C patent/CY2017026I2/el unknown
-
2018
- 2018-04-18 HR HRP20180615TT patent/HRP20180615T1/hr unknown
-
2019
- 2019-01-04 US US16/239,839 patent/US20200017442A1/en not_active Abandoned
- 2019-11-07 HR HRP20192022TT patent/HRP20192022T1/hr unknown
-
2020
- 2020-04-29 US US16/862,125 patent/US20220306578A1/en not_active Abandoned
-
2022
- 2022-07-08 US US17/860,589 patent/US20230142119A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2017017I1 (lt) | Tetraciklinis junginys | |
LTPA2020505I1 (lt) | Nauji tricikliniai junginiai | |
BR112012006859A2 (pt) | compostos | |
DK2427449T3 (da) | Vinylindazolylforbindelser | |
BRPI1013868A2 (pt) | composto diaciletilenodiamina | |
BRPI1008774A2 (pt) | espiroamida substituída | |
BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
DE112010004215A5 (de) | Hydrostataktor | |
DE112010002949A5 (de) | Kupplungstastpunkte | |
BRPI1005525A2 (pt) | compostos de azaazuleno | |
ECSP12011999A (es) | Derivados benzamida sustituidos | |
BRPI1008827A2 (pt) | deisobutenizador | |
BRPI1014968A2 (pt) | subalargador | |
DE112010002728A5 (de) | Turboinhalator | |
BR112012003868A2 (pt) | Compostos orgânicos | |
DE112009005323A5 (de) | Hebelarmprüfmaschine | |
UY33156A (es) | Nuevos compuestos tienopirrol | |
DE112010004249A5 (de) | Spindelaktor | |
DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
BRPI1008070A2 (pt) | tricianoboratos | |
BR112012004964A2 (pt) | girocóptero | |
DE112010003255A5 (de) | Fördergutverteiler | |
BRPI1010159A2 (pt) | bistuti | |
BR112012009784A2 (pt) | composto benzazepínico | |
BR112012003616A2 (pt) | metilpirroloprimidinacarboxamidas |